Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019067015) CHIMERIC ANTIGEN RECEPTORS AND BISPECIFIC ANTIBODIES FOR TREATMENT OF MANTLE CELL LYMPHOMA
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/067015 International Application No.: PCT/US2018/031232
Publication Date: 04.04.2019 International Filing Date: 04.05.2018
IPC:
C07K 16/28 (2006.01) ,C07K 16/30 (2006.01) ,A61P 35/00 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
30
from tumour cells
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
CITY OF HOPE [US/US]; 1500 East Duarte Road Duarte, California 91010, US
Inventors:
QIN, Hong; US
KWAK, Larry; US
WEI, Guowei; US
Agent:
MEIKLEJOHN, Anita, L.; US
Priority Data:
62/566,02029.09.2017US
Title (EN) CHIMERIC ANTIGEN RECEPTORS AND BISPECIFIC ANTIBODIES FOR TREATMENT OF MANTLE CELL LYMPHOMA
(FR) RÉCEPTEURS D'ANTIGÈNES CHIMÉRIQUES ET ANTICORPS BISPÉCIFIQUES POUR LE TRAITEMENT DU LYMPHOME À CELLULES DU MANTEAU
Abstract:
(EN) Provided herein are, inter alia, compositions and methods for the treatment of cancer. The compositions include, for example, a chimeric antigen receptor or a bispecific antibody comprising a free immunoglobulin light chain VL, inter alia, useful for targeting and killing human mantel cell lymphoma (MCL) cells. Due to their ability to differentially bind MCL cells versus non-cancer cells, the compositions provided herein may be used, for example, for therapeutic and diagnostic purposes.
(FR) La présente invention concerne entre autres, des compositions et des méthodes de traitement du cancer. Les compositions selon l'invention, comprennent, par exemple, un récepteur d'antigène chimérique ou un anticorps bispécifique comprenant une chaîne légère d'immunoglobuline libre VL, entre autres, utile pour cibler et éliminer des cellules de lymphome à cellule du manteau humain (MCL). Les compositions selon l'invention peuvent être utilisées, par exemple, à des fins thérapeutiques et diagnostiques, en raison de leur capacité à se lier de manière différentielle à des cellules MCL par rapport à des cellules non cancéreuses.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)